Abstract 15P
Background
A significant number of cancer patients do not benefit from PD-L1/PD-1 blockade immunotherapies. PD-1 and LAG-3 co-upregulation in T-cells is one of the major mechanisms of resistance by establishing a highly dysfunctional state in T-cells.
Methods
A high-throughput screening was performed of PD-1/LAG-3 multiomic expression profiles in public databases of human cancer biopsies, to establish relationships between infiltrating tumor-infiltrating PD-1/LAG-3 T cells with biomarkers both in T cells and within the tumour microenvironment. These results were validated in engineered T-cell lines with constitutively active PD-1, LAG-3 pathways, and their combination, analysed by high-throughput quantitative proteomics and validated by conventional molecular techniques on primary T cells from NSCLC patients.
Results
The high-throughput multiomic human cancers screening and the experimental proteomic T cell lines uncovered a strong PD-1/LAG-3 dysfunctionality signature that was found which regulated immune, proteomic, metabolic, genetic, and epigenetic pathways. These mainly relied on differential regulation of E3 ubiquitin ligases CBL-B and C-CBL. Notably, LAG-3 expression has never been associated to CBL ubiquitin ligases before.
Conclusions
PD-1/LAG-3 co-signaling profile uncovers a highly dysfunctional regulated programme. Co-blockade with a bispecific drug but not with a combination of anti-PD-1/anti-LAG-3 antibodies achieved both CBL-B and C-CBL inhibition, reverting T-cell dysfunctionality in lung cancer patients resistant to PD-L1/PD- 1 blockade. These results will help identifying the mechanisms of intrinsic resistance to PD-1 blockade mediated by LAG-3 co-signaling.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Navarrabiomed.
Funding
This research was supported by: The Spanish Association against Cancer (AECC), PROYE16001ESCO; Instituto de Salud Carlos III (ISCIII)-FEDER Project grants FIS PI20/00010, COV20/00000, and TRANSPOCART ICI19/00069; Biomedicine Project Grant from the Department of Health of the Government of Navarre-FEDER funds (BMED 050-2019, 51-2021); Strategic projects from the Department of Industry, Government of Navarre (AGATA, Ref. 0011-1411-2020-000013; LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); European Union Horizon 2020 ISOLDA project, under grant agreement ID: 848166. L.C. is financed by Instituto de Salud Carlos III (ISCIII), co-financed by FEDER funds, "Contratos PFIS: contratos predoctorales de formación en investigación en salud" (FI21/00080); M.E. is financed by the Navarrabiomed- Fundación Miguel Servet predoctoral contract.
Disclosure
C.J. Edwards: Other, Personal, Other, Declares to be inventor of the Humabody CB213 (WO/2019/158942. 603 Crescendo Biologics Ltd.): Crescendo Biologics. J. Leggs: Other, Declares to be e inventor of the Humabody CB213 (WO/2019/158942. 603 Crescendo Biologics Ltd.): Crescendo Biologics. D. Escors: Other, Declares to be e inventor of the Humabody CB213 (WO/2019/158942. 603 Crescendo Biologics Ltd.): Navarrabiomed. All other authors have declared no conflicts of interest.
Resources from the same session
514P - Immunophenotypic profile of glioblastoma microenvironment: A cohort study
Presenter: Lidia Gatto
Session: Poster session 09
515P - A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients
Presenter: Shu Zhou
Session: Poster session 09
516P - Building a new prognostic score for patients with central nervous system (CNS) tumors enrolled in early phase clinical trials
Presenter: Kristi Beshiri
Session: Poster session 09
517P - Differentiating IDH-wildtype and IDH-mutant high grade gliomas with deep learning
Presenter: Katherine Hewitt
Session: Poster session 09